Home Biotech Endonovo Therapeutics Inc. (OTCMKTS:ENDV) Posts Topline Interim Results

Endonovo Therapeutics Inc. (OTCMKTS:ENDV) Posts Topline Interim Results

SHARE
Endonovo Therapeutics Inc. (OTCMKTS:ENDV)
Healthcare Technology and Medical Scan of a Body Diagnosis

Endonovo Therapeutics Inc.

(OTCMKTS:ENDV)

Shares of Endonovo Therapeutics Inc. (OTCMKTS:ENDV) gained 0.23% after the developer of non-invasive electroceuticals issued an update on a study assessing the effectiveness of its Immunotronics platform. Interim clinical trial results indicate improved cardiac function and less ventricular remodeling.

Endonovo Therapeutics Inc. (OTCMKTS:ENDV)

ENDV Stock Investor’s Reaction

Release of the interim results follows the announcement of a settlement and dismissal of a lawsuit pitting the company against the Kodiak Capital Group. The developments have helped boost investor confidence in Endonovo Therapeutics Inc. (OTCMKTS:ENDV).

Buoyed by the positive interim results for the Immunotronics platform, Endonovo Therapeutics Inc. (OTCMKTS:ENDV) has announced plans to conduct additional pre-clinical studies using the electroceuticals technology

“We not only want to demonstrate the effectiveness of our non-invasive electroceuticals, but we also want to create an easy to use device that can reduce the treatment time required to produce a meaningful effect. Our belief is that the future of medicine is electric and that our non-implantable and non-invasive electroceuticals platform will be at the forefront of bioelectronics medicine,” said CEO Alan Collier.

In addition to the Immunotronics platform study, Endonovo Therapeutics Inc. (OTCMKTS:ENDV) has commenced additional pre-clinical studies on Critical Limb Ischemia Kidney disease and Non-Alcoholic Steatohepatitis. However, the company remains reluctant to project when the studies will be completed after failing to meet key deadlines in the past.

The company claims to have sufficient funds to finance development projects until the end of the year.

Kodiak Capital Group Settlement

Separately, Endonovo Therapeutics Inc. (OTCMKTS:ENDV) has reached a settlement agreement with Kodiak Capital Group over claims arising from equity investment. Under the terms, the investment firm is to return 2.1 million shares of Endonovo’s common stock.

In return, Endonovo Therapeutics Inc. (OTCMKTS:ENDV) is to pay Kodiak $80,000, which was deposited with the court last year. The two companies have also agreed to terminate their Securities Purchase Agreement, Equity Purchase agreement, and Registration Rights Agreement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ENDV and receive breaking news on other hot stocks by signing up for our free newsletter!

LEAVE A REPLY